U.S. flag

An official website of the United States government

Filters

See more specimen types...

Other countries

Results: 1 to 20 of 40

Tests names and labsConditionsGenes, analytes, and microbesMethods

CYP2C19 - NGS including CNV analysis

Centogene AG - the Rare Disease Company
Germany
11
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Polypharmacy Comprehensive Panel

Invitae
United States
3324
  • D Deletion/duplication analysis
  • T Targeted variant analysis

Clopidogrel, impaired responsiveness to, 609535, Autosomal recessive (Resistance to clopidogrel) (MLPA)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • D Deletion/duplication analysis

Clopidogrel, impaired responsiveness to, 609535, Autosomal recessive (Resistance to clopidogrel) (CYP2C19 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Mephenytoin poor metabolizer, 609535, Autosomal recessive (Resistance to clopidogrel) (CYP2C19 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Mephenytoin poor metabolizer, 609535, Autosomal recessive (Resistance to clopidogrel) (MLPA)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • D Deletion/duplication analysis

Proguanil poor metabolizer, 609535, Autosomal recessive (Resistance to clopidogrel) (MLPA)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • D Deletion/duplication analysis

Proguanil poor metabolizer, 609535, Autosomal recessive (Resistance to clopidogrel) (CYP2C19 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

CYP2C19 (CYP2C19 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Omeprazole poor metabolizer, 609535, Autosomal recessive (Resistance to clopidogrel) (MLPA)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • D Deletion/duplication analysis

Omeprazole poor metabolizer, 609535, Autosomal recessive (Resistance to clopidogrel) (CYP2C19 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Warfarin Genotyping (CYP2C9, VKORC1, CYP4F2, rs12777823)

IU Genetic Testing Laboratories Indiana University School of Medicine
United States
24
  • T Targeted variant analysis

CYP2C cluster rs12777823 Genotyping

IU Genetic Testing Laboratories Indiana University School of Medicine
United States
11
  • T Targeted variant analysis

Pharmacogenomics Test Panel

IU Genetic Testing Laboratories Indiana University School of Medicine
United States
813
  • T Targeted variant analysis

CYP2C19 Genotyping

IU Genetic Testing Laboratories Indiana University School of Medicine
United States
11
  • T Targeted variant analysis

CYP450 Panel - TCA/SSRI

Molecular Diagnostics Children's Hospital of Wisconsin
United States
22
  • D Deletion/duplication analysis
  • T Targeted variant analysis

Pharmacogenetics Panel

Mako Medical Laboratories
United States
66
  • D Deletion/duplication analysis
  • T Targeted variant analysis

CYP450 drug metabolizing enzyme mutation panel

Molecular Diagnostics Children's Hospital of Wisconsin
United States
33
  • T Targeted variant analysis

CYP2C19 drug metabolizing enzyme gene mutation

Molecular Diagnostics Children's Hospital of Wisconsin
United States
11
  • T Targeted variant analysis

Clopidogrel response

Xcode Life
India
21
  • T Targeted variant analysis

Results: 1 to 20 of 40

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.